Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 9 of 14, showing 10 Applications out of 133 total, starting on record 81, ending on 90

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

81.

ECCT/19/10/02   AMC-100
    A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals with Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)   
Principal Investigator(s)
1. NAFTALI WISINDI BUSAKHALA
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTER
 
01-04-2020 View

82.

ECCT/19/11/01   A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults.
    Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.   
Principal Investigator(s)
1. Melissa Kapulu
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
07-08-2021 View

83.

ECCT/19/02/01   DANCE Study
    An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg.   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
2. Isaac Tsikhutsu
Site(s) in Kenya
1. Nyanza Reproductive Health Society (Kisumu county)
2. Kenya Medical Research Institute (Kisumu county)
3. Kenya Medical Research Institute, Walter Reed Project (Kericho county)
 
14-08-2019 View

84.

ECCT/19/01/01   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu Ragama
Site(s) in Kenya
1. Ahero County hospital (Kisumu county)
2. Siaya County Hospital (Siaya county)
 
13-08-2019 View

85.

ECCT/18/07/02   CONRAD RING
    Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya   
Principal Investigator(s)
1. DR. NELLY RWAMBA MUGO
Site(s) in Kenya
KEMRI CRC
 
22-09-2018 View

86.

ECCT/18/06/04   RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA
    BUSIA LEVEL IV HOSPITAL   
Principal Investigator(s)
1. BENARD OCHIENG WESONGA
Site(s) in Kenya
Busia Level IV Hospital
 
29-07-2019 View

87.

ECCT/18/07/07   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. GRACE KIRINGA KAGUTHI
Site(s) in Kenya
1. Center for Respiratory Diseases Research (Siaya county)
2. KEMRI (Kisumu county)
 
04-10-2018 View

88.

ECCT/18/04/01   CKAF156 STUDY
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. KEMRI CDC (Siaya county)
2. Walter Reed Project (Kisumu county)
 
23-08-2018 View

89.

ECCT/18/07/01   CCNO17 Male contraception study.
    Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception.       
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
Couples counselling Center
 
19-11-2018 View

90.

ECCT/18/04/03   ShangRing vs. Mogen Clamp for EIMC
    Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision in sub-Saharan Africa       
Principal Investigator(s)
1. Richard Lee
2. Mark Barone
Site(s) in Kenya
1. Homa Bay Teaching and Referral Hospital (Homa Bay county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
10-12-2018 View